Showing all 3 results
Losartan Potassium Hydrochlorothiazide Tablets
FreeProduct Composition & Strength
We supply this product as Film Coated Tablets (typically Yellow or White, Oval). The coating protects the hygroscopic Losartan from moisture.
Active Ingredient Strength (Standard) Therapeutic Role Losartan Potassium USP/BP 50 mg Vasodilator (ARB) Hydrochlorothiazide USP/BP 12.5 mg Diuretic (Thiazide) (High Strength Variant) 100 mg Losartan + 25 mg HCTZ Severe Hypertension Excipients Q.S. Microcrystalline Cellulose / Lactose / Magnesium Stearate Filler / Lubricant Losartan Potassium, Amlodipine Besylate Tablets
FreeProduct Composition & Strength
We supply this product as Film Coated Tablets (typically White or Yellow, Oval/Round). The formulation uses the Besylate salt of Amlodipine for maximum stability.
Active Ingredient Strength (Standard) Therapeutic Role Losartan Potassium USP/BP 50 mg Vasodilator (ARB) Amlodipine Besylate USP/BP 5 mg (Eq. to Base) Vasodilator (CCB) (High Strength Variant) 50 mg Losartan + 10 mg Amlodipine
100 mg Losartan + 5 mg AmlodipineResistant Hypertension Excipients Q.S. Microcrystalline Cellulose / Sodium Starch Glycolate Filler / Super-Disintegrant Losartan Tablet
FreeProduct Composition & Available Strengths
We supply Losartan Potassium across the complete, internationally recognized therapeutic range to facilitate progressive dose titrations and precise maintenance regimens.
Active Ingredient Monograph Available Strengths Formulation Matrix Delivery System Primary Clinical Application Losartan Potassium USP / BP / IP 25 mg Oral Solid Film-Coated Tablet Pediatric & Low-Dose Titration: For introductory pediatric hypertension care or initial combination-therapy building. Losartan Potassium USP / BP / IP 50 mg Oral Solid Film-Coated Tablet Core Commercial Volume: Standard international baseline daily dose for mild-to-moderate chronic essential hypertension. Losartan Potassium USP / BP / IP 100 mg Oral High-Potency Solid Tablet Maximal Saturation Maintenance: For advanced hypertensive management, diabetic nephropathy progression delay, and stroke risk reduction in left ventricular hypertrophy.
